Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 350 versus UROVIST MEGLUMINE DIU CT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 350 versus UROVIST MEGLUMINE DIU CT.
OMNIPAQUE 350 vs UROVIST MEGLUMINE DIU/CT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
1-2 mL/kg IV up to 150 mL for CT; 30-50 mL IV for DSA; max 350 mL per procedure.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent